Sri Lanka Medical Device Market Entry Roadmap

1. Key takeaways

Market entry for medical devices in Sri Lanka can be broken down into six steps: first, determine the category (general device Class I to III / IVD Class A to D / listed device); second, appoint a local Sri Lankan MAH; third, compile the dossier (FMSA plus PRD or PRD only, according to the route); fourth, complete the online form, submit in person and pay the fees; fifth, where required, obtain the Sample Import Licence (SIL) and submit samples for testing; sixth, after MDEC review is passed, receive the registration certificate and the import licence. Each step has its own formal requirements, from the binding format of the dossier to the order in which payment happens, and several of them are counter-intuitive for teams that have worked in neighbouring markets. The sequence below follows the NMRA procedures as published, and the observations in the later sections explain where projects most often go wrong.

• Classification comes first and decides the dossier structure and the available routes.
• A local MAH must be appointed before the application is submitted.
• The dossier is either combined (FMSA plus PRD) or PRD only, depending on the product category.
• The online form is completed before the paper dossier is submitted in person, and fees follow acceptance.
• Sample import and testing apply to some products and are a major schedule variable.

2. Legal basis

The table below sets out each step of the entry process with its key points and its source, from the classification determination through dossier compilation, submission and payment, sample requirements, and the issue of the certificate, together with the binding requirements for the physical file.

3. Expert insights

Insight 1: the online form is not the submission; it is a preparatory step before the submission. The NMRA procedure is to complete the online Google form first and then submit the paper dossier in person. Completing the online form alone does not constitute a completed application, which is the exact opposite of markets such as Pakistan, where the portal is mandatory and paper filings are not accepted. This is the easiest point to get wrong in this market: teams arriving from portal-first markets assume that the online step finishes the job, while the file only enters the process when the paper dossier reaches the counter. The distinction should be stated explicitly in the project plan so that nobody treats the form confirmation as an application receipt.

Insight 2: payment happens after the acceptance check, not before. The receiving officer first checks the completeness of the documents against the checklist and only then issues the payment slip. This means that a dossier with missing documents does not even reach the payment stage; it is simply not accepted. The practical effect is that document completeness is a gate that operates before any fee is paid, so there is no partial credit for an incomplete filing. Pre-submission completeness checks against the official checklist are therefore not optional quality housekeeping but the step that determines whether the submission happens at all on the intended day.

Insight 3: the sample stage is the main variable in the timeline. The low-risk pathway (Annex 1 of GL-037) exempts end-user performance evaluation; the reliance pathway exempts sample import and performance evaluation, but does not apply to Class III. Whether the sample testing stage can be skipped essentially determines the magnitude of the project timeline. Where samples must be imported under a SIL and tested locally, the logistics of the samples, the queue at the testing laboratory and the reporting time all stack onto the schedule. Route eligibility checks should therefore be completed before the timeline is committed to the client, and the sample workstream should carry its own buffer.

4. Practical recommendations

• Mark the skippable items on the route map given to the client: first judge whether the product falls within the low-risk list of Annex 1 of GL-037, which can waive the FMSA and performance evaluation.
• Then judge whether the product holds approvals from recognised reference countries, which opens the reliance pathway, except for Class III.
• Once these two judgements are made, the timeline and the budget can be given as ranges instead of the answer that it depends, which is what clients need for internal approval of the project.
• Prepare the physical dossier to the binding requirements from the outset, with the green-tape box files and the full cover information, so that the acceptance check on the day of submission passes at the first attempt.
• Complete the online form only when the paper dossier is ready to be filed in person, and treat the two actions as a single coordinated step in the plan.

5. Verification checklist

• □ The classification determination has been completed (including the listed device judgement).
• □ A local MAH has been appointed and the LOA signed.
• □ The dossier route has been determined (FMSA + PRD / PRD only).
• □ The online application form has been completed.
• □ The dossier has been prepared to the binding requirements and submitted at the Tuesday window.
• □ Payment has been completed and the dossier number obtained.
• □ The arrangement for sample import and testing has been scheduled.

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com